{
    "nct_id": "NCT06467357",
    "official_title": "DESTINY-Biliary Tract Cancer-01: A Phase 3 Study of Trastuzumab Deruxtecan (T-DXd) and Rilvegostomig Versus Standard-of-Care Gemcitabine, Cisplatin, and Durvalumab for First Line Locally Advanced or Metastatic HER2-expressing Biliary Tract Cancer",
    "inclusion_criteria": "* Participants must be â‰¥ 18 years of age at the time of screening. Other age restrictions may apply as per local regulations;\n* Male and female;\n* Unresectable, previously untreated, locally advanced or metastatic BTC. Prior treatment in the perioperative and/or adjuvant setting is permissible provided there is > 6 months (180 days) between the end of adjuvant treatment and the diagnosis of locally advanced or metastatic disease.\n* histologically confirmed HER2-expressing (IHC 3+ or IHC 2+) BTC;\n* Provision of FFPE tumor sample that is no older than 3 years;\n* At least one target lesion assessed by the Investigator based on RECIST v1.1 (randomized portion only);\n* WHO/ECOG performance status of 0 or 1;\n* Adequate organ and bone marrow function within 14 days before randomization;\n* Evidence of post-menopausal status or negative serum pregnancy test for females of childbearing potential;\n\nKey\nHealthy volunteers allowed\nMust have minimum age of 18 Years\nMust have maximum age of 99 Years",
    "exclusion_criteria": "* Prior exposure to other HER2 targeting therapies, ADCs, immune checkpoint inhibitors and therapeutic anticancer vaccines;\n* histologically confirmed ampullary carcinoma;\n* history of substance abuse or any other medical conditions such as clinically significant cardiac or psychological conditions;\n* spinal cord compression or clinically active central nervous system metastases, defined as untreated and symptomatic, or requiring therapy with corticosteroids or anticonvulsants to control associated symptoms;\n* medical history of myocardial infarction within 6 months before randomization/enrollment, symptomatic congestive heart failure (New York Heart Association Class II to IV), unstable angina pectoris, clinically important cardiac arrhythmias, or a recent (< 6 months) cardiovascular event including stroke;\n* Serious chronic gastrointestinal conditions associated with diarrhea (eg, active inflammatory bowel disease); active non-infectious skin disease (including any grade rash, urticaria, dermatitis, ulceration, or psoriasis) requiring systemic treatment;\n* active autoimmune, connective tissue or inflammatory disorders that has required systemic treatment in the past 2 years, or where there is documented, or a suspicion of pulmonary involvement at the time of screening;\n* Corrected QT interval (QTcF) prolongation to > 470 msec (females) or > 450 msec (males) based on average of the screening triplicate 12-lead ECG;\n* History of (non-infectious) ILD/pneumonitis, has current ILD/pneumonitis, or where suspected ILD/pneumonitis cannot be ruled out by imaging at screening;\n* Lung-specific intercurrent clinically significant illnesses including, but not limited to, any underlying pulmonary disorder;\n* Prior pneumonectomy (complete);\n* Uncontrolled infection requiring IV antibiotics, antivirals, or antifungals;\n* Active primary immunodeficiency, known uncontrolled active HIV infection or HCV;\n* Pregnant or breastfeeding female patients, or patients who are planning to become pregnant;\n* Participation in another clinical study with a study intervention or investigational medicinal device administered in the last 6 months prior to randomization, or concurrent enrollment in another clinical study, unless it is an observational (non-interventional) clinical study or during the follow-up period of an interventional study (only randomized portion).",
    "miscellaneous_criteria": "Key"
}